Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
NCT03878199Phase 2Terminated
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Feb 2019
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in Myeloproliferative Neoplasm (MPN) and acute myeloid leukemia (AML), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Dose Limiting Toxicity and Acute Leukemia Response-Partial Response. Started Feb 2019; status: terminated.
02
Drugs
03
Conditions
Myeloproliferative Neoplasm (MPN)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03878199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878199.